OncoSec Touts Encouraging Early Data For Opdivo Combined Immunotherapy For Skin Cancer

·1 min read
  • OncoSec Medical Incorporated (NASDAQ: ONCS) announced early clinical data from an investigator-sponsored trial of TAVO in combination with Bristol-Myers Squibb Co's (NYSE: BMY) intravenous Opdivo (nivolumab).

  • TAVO is OncoSec's proprietary interleukin 12 (IL-12) encoding plasmid delivered by intratumoral electroporation (TAVO-EP).

  • The trial enrolled patients with high-risk operable locoregional advanced stage IIIB-D or stage IVA melanoma.

  • Related: OncoSec Cuts Workforce, Prioritizes Pipeline.

  • A preoperative overall response rate was observed in 7 of 10 patients (70%) consisting of 4 patients with complete response (CR) and three patients with partial response (PR).

  • Two patients had stable disease, and one showed progressive disease.

  • One patient with a PR declined surgery due to a significant response after neoadjuvant treatment.

  • At the time of surgery, 8 of 9 (88.9%) evaluated patients had a major pathologic response, and 6 of 9 patients (66.7%) had a pathological CR. No disease recurrence has been observed at a median follow-up of 7 months from the surgery date.

  • Overall, the combination treatment was well tolerated, and no patient discontinued neoadjuvant treatment due to toxicity. Patients continue to enroll.

  • Price Action: ONCS shares are up 1.99% at $4.10 during after-hours trading on Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.